Neurology · 1985 · 18 citations · 0 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyCardiac MedicationsMovement Disorder PharmacotherapyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersOpen-label TrialsParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease Treatment
In a 12-month open-label trial, pergolide mesylate was administered in doses with antiparkinsonian efficacy to six patients with stable heart disease. Cardiac status did not worsen in any patient. Parkinson's disease improved in all patients. Pergolide is a safe and effective therapy for Parkinson's disease, even in patients with heart disease.